Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

第1相 実施中（募集終了） NCT03696784

概要

This research study combines 2 different ways of fighting disease: antibodies and T cells. Both antibodies and T cells have been used to treat patients with cancers, and both have shown promise, but neither alone has been sufficient to cure most patients. This study combines both T cells and antibodies to create a more effective treatment. The treatment being researched is called autologous T lymphocyte chimeric antigen receptor cells targeted against the CD19 antigen (ATLCAR.CD19) administration. Prior studies have shown that a new gene can be put into T cells and will increase their ability to recognize and kill cancer cells. The new gene that is put in the T cells in this study makes a piece of an antibody called anti-CD19. This antibody sticks to leukemia cells because they have a substance on the outside of the cells called CD19. For this study, the anti-CD19 antibody has been changed so that instead of floating free in the blood part of it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD19 chimeric (combination) receptor-activated T cells seem to kill some of the tumor, but they do not last very long i

Number of Participants With Treatment-emergent Grade ≥ 3 Adverse Events Per National Cancer Institute's Common Terminology Criteria

Up to 4 weeks · Participants

Number of Participants With Treatment-emergent Grade ≥ 3 Adverse Events Per Cytokine Release Syndrome (CRS)

Up to 4 weeks · Participants

Number of Participants With Treatment-emergent Grade ≥ 3 Adverse Events Per Immune Effector Cell-associated Neurotoxicity Syndrome (ICANS)

Up to 4 weeks · Participants

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

• A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Ve — Hoffmann-La Roche
• Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diag — National Cancer Institute (NCI)
• Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating — National Cancer Institute (NCI)
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Tr — National Cancer Institute (NCI)
• Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibruti — National Cancer Institute (NCI)
• An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymph — Acerta Pharma BV

すべての治験